Eli Lilly Other Intangible Assets, Net increased by 1.2% to $6.52B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $6.17B to $6.52B. Over 5 years (FY 2020 to FY 2025), Other Intangible Assets, Net shows a downward trend with a -2.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
A high value indicates a strong portfolio of intellectual property, while a declining value may signal the approaching expiration of key patents.
This includes identifiable non-physical assets such as patents, trademarks, licenses, and acquired drug rights, net of a...
Crucial for comparing the strength of drug pipelines and competitive advantages among pharmaceutical peers.
other_intangibles_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.99B | $7.89B | $7.69B | $7.48B | $7.50B | $7.12B | $7.21B | $7.09B | $6.90B | $6.78B | $6.91B | $6.76B | $6.64B | $6.54B | $6.17B | $6.01B | $5.91B | $6.45B | $6.52B |
| QoQ Change | — | -1.2% | -2.5% | -2.7% | +0.2% | -5.0% | +1.2% | -1.7% | -2.6% | -1.8% | +1.8% | -2.1% | -1.9% | -1.5% | -5.7% | -2.5% | -1.7% | +9.1% | +1.2% |
| YoY Change | — | — | — | — | -6.1% | -9.7% | -6.3% | -5.3% | -7.9% | -4.8% | -4.2% | -4.6% | -3.9% | -3.6% | -10.7% | -11.1% | -11.0% | -1.4% | +5.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.